Literature DB >> 2479178

The role of interferons in the treatment of malignant neoplasms.

J R Murren1, A C Buzaid.   

Abstract

Interferons (IFNs) are proteins with a wide range of biological effects. IFNs have antiviral and antiproliferative properties. They modulate both the immune system and the expression of cell phenotype. In the past decade, the IFNs have received intense clinical scrutiny. Alpha IFN is the best studied and displays activity in many neoplastic diseases; it has shown the most promise in the hematological cancers although several solid tumors, including epidemic Kaposi's sarcoma, renal cell carcinoma, and melanoma, respond. No neoplastic disease, however, has been cured by the IFNs. IFN seems to be most active in the setting of minimal residual disease, and clinical studies evaluating its role in the adjuvant setting are under way. Other areas of research include trials combining IFN with cytotoxic drugs or other biological response modifiers, and maintenance IFN to prolong remissions following successful induction therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2479178      PMCID: PMC2589121     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  208 in total

1.  Interferon-mediated protein kinase and low-molecular-weight inhibitor of protein synthesis.

Authors:  W K Roberts; A Hovanessian; R E Brown; M J Clemens; I M Kerr
Journal:  Nature       Date:  1976-12-02       Impact factor: 49.962

2.  Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa-2a by intramuscular injection.

Authors:  L M Itri; M Campion; R A Dennin; A V Palleroni; J U Gutterman; J E Groopman; P W Trown
Journal:  Cancer       Date:  1987-02-01       Impact factor: 6.860

Review 3.  Pharmacokinetics and side effects of interferon in man.

Authors:  T C Merigan
Journal:  Tex Rep Biol Med       Date:  1977

4.  Clinical and laboratory investigations on man: systemic administration of potent interferon to man.

Authors:  H Strander; K Cantell; G Carlström; P A Jakobsson
Journal:  J Natl Cancer Inst       Date:  1973-09       Impact factor: 13.506

5.  Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma.

Authors:  A C Louie; J G Gallagher; K Sikora; R Levy; S A Rosenberg; T C Merigan
Journal:  Blood       Date:  1981-10       Impact factor: 22.113

6.  Application of human leucocyte interferon in patients with carcinoma of the uterine cervix.

Authors:  D Ikić; J Krusić; V Kirhmajer; M Knezević; Z Maricić; B Rode; D Jusić; E Soos
Journal:  Lancet       Date:  1981-05-09       Impact factor: 79.321

7.  Application of human leucocyte interferon in patients with tumours of the head and neck.

Authors:  D Ikić; I Padovan; I Brodarec; M Knezević; E Soos
Journal:  Lancet       Date:  1981-05-09       Impact factor: 79.321

8.  Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma.

Authors:  J U Gutterman; G R Blumenschein; R Alexanian; H Y Yap; A U Buzdar; F Cabanillas; G N Hortobagyi; E M Hersh; S L Rasmussen; M Harmon; M Kramer; S Pestka
Journal:  Ann Intern Med       Date:  1980-09       Impact factor: 25.391

9.  Interferon therapy in myelomatosis.

Authors:  H Mellstedt; A Ahre; M Björkholm; G Holm; B Johansson; H Strander
Journal:  Lancet       Date:  1979-02-03       Impact factor: 79.321

10.  Randomized trial of standard therapy with or without poly I:C in patients with superficial bladder cancer.

Authors:  N Kemeny; A Yagoda; Y Wang; K Field; H Wrobleski; W Whitmore
Journal:  Cancer       Date:  1981-11-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.